# OnCo record paper-alta-jco-2017 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-alta-jco-2017/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-alta-jco-2017" ;
  schema:name "Brigatinib in patients with crizotinib-refractory ALK-positive non-small-cell lung cancer: a randomized, multicenter phase II trial (ALTA)"@en ;
  schema:description "The primary report of ALTA: after crizotinib, brigatinib shrank tumours in about half of patients, more so at the 180 mg dose after a week at 90 mg, and held the disease for around a year."@en ;
  schema:url <https://onco.cc/key-papers/paper-alta-jco-2017/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://doi.org/10.1200/JCO.2016.71.5904>, <https://pubmed.ncbi.nlm.nih.gov/28475456/>, <https://clinicaltrials.gov/study/NCT02094573> ;
  schema:sameAs <https://doi.org/10.1200/JCO.2016.71.5904> ;
  schema:datePublished "2017"^^xsd:gYear ;
  schema:author "Kim DW, Tiseo M, Ahn MJ, et al." ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/alk-positive-nsclc/> ;
  onco:targets <https://onco.cc/targets/alk/> ;
  onco:drugs <https://onco.cc/drugs/brigatinib/> ;
  onco:companies <https://onco.cc/companies/takeda/> ;
  onco:trials <https://onco.cc/trials/alta/> ;
  onco:people <https://onco.cc/people/kim-dong-wan/>, <https://onco.cc/people/ross-camidge/> ;
  onco:journals <https://onco.cc/journals/jco/> .